Therefore, the use of PCSK9 inhibitors, especially in patients with hypercholesterolemia, should reduce this adverse effect and improve the antiviral efficiency of the organism related to INF-β [107]. This evidence concerns the gene PCSK9 and familial hypercholesterolemia.